Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Medical Sciences Division is delighted to welcome Dr Anjan Thakurta to Oxford, having now taken up his position of Visiting Professor of Cancer, Biology and Translational Science within the Radcliffe Department of Medicine.

None

Dr Thakurta will provide strategic support and advice to the Medical Sciences Division and foster new collaborations between the University of Oxford and Celgene. He will also facilitate greater access to and opportunities with senior Celgene scientists for University of Oxford researchers, enabling them to gain a deeper understanding of the scope and potential of Celgene’s portfolio of work and an industry perspective on research questions. Whilst in Oxford, Dr Thakurta will be based in the MRC Weatherall Institute of Molecular Medicine (MRC WIMM).

Dr Thakurta brings extensive knowledge of Celgene’s early therapeutic pipeline and translational biology programmes, especially in haematology / oncology, and over 20 years’ experience in translational and clinical drug development. Most recently, leading the myeloma disease team, one of Celgene’s major disease areas. Prior to this, he led translational and diagnostic work across all haematological areas in Celgene.

Dr Thakurta brings with him a wealth of experience in mentoring scientists in the early stages of their careers, and has previously supervised Oxford-Celgene fellows.  His advice on Oxford-Celgene Fellowship Programme applications will not only support the development of cutting-edge science, but also the training of the next generation of scientists and clinical academics.

 

As Visiting Professor, I will visit Oxford regularly, interact with current and potential future fellows and look forward to establishing some new and exciting collaborations and translational initiatives at the university over the next three years. - Dr Anjan Thakurta, Celgene

 

I am really pleased Dr Thakurta has been awarded the position of Visiting Professorship and has taken this up position. Dr Thakurta has a wealth of experience in drug development especially in haematological disease and has already mentored two young aspiring clinical academics, who have successfully started their independent careers in Oxford. He has also made important links with a number of Oxford groups and I am sure these new relationships will be enormously productive, helping to transform patient care as well as providing wonderful academic opportunities for Oxford University, Oxford University Hospitals NHS Foundation Trust and Celgene - Professor Paresh Vyas, Professor of Haematology, MRC Molecular Haematology Unit, MRC WIMM, University of Oxford

 

Similar stories

Moonshot initiative to develop affordable COVID-19 antivirals gets funding boost

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from the Wellcome Trust, on behalf of the Covid-19 Therapeutics Accelerator.

NHS garden in full bloom at RHS Chelsea Flower Show

The sun was shining for the RHS Chelsea Flower show press day earlier this week. One garden in particular bloomed particularly brightly, with the 'Finding Our Way: An NHS Tribute Garden' getting plenty of attention.

University of Oxford launches Podium Analytics Institute for Youth Sports Medicine and Technology

Oxford University has been selected as the home of the new Podium Analytics Institute for Youth Sports Medicine and Technology. This will be the world’s first academic Institute focused on young athletes’ safety and lifelong health and will combine Oxford’s longstanding tradition in sports and education with the very best of science, medicine, and technology.

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.